Search

ADMA Biologics Inc

Avatud

SektorTervishoid

9.47 0.64

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.23

Max

9.52

Põhinäitajad

By Trading Economics

Sissetulek

-7.5M

38M

Müük

9.9M

124M

P/E

Sektori keskmine

13.929

57.002

Aktsiakasum

0.16

Kasumimarginaal

30.405

Töötajad

640

EBITDA

-3.8M

57M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+80.66% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. nov 2026

Turustatistika

By TradingEconomics

Turukapital

158M

2.2B

Eelmine avamishind

8.83

Eelmine sulgemishind

9.47

Uudiste sentiment

By Acuity

100%

0%

325 / 340 Pingereas Healthcare

ADMA Biologics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. aug 2026, 20:02 UTC

Social Media

ADMA Biologics shares are lower amid concerns over financial practices and potential SEC scrutiny, despite claims of an internal review clearing the company.

12. aug 2026, 19:46 UTC

ADMA Biologics shares are trading lower today, despite broader market gains following a positive inflation report. The stock remains near its one-month high.

11. aug 2026, 22:56 UTC

ADMA Biologics Inc shares are lower in after-market hours following an earlier decline. The price remains above its 20-day moving average.

7. aug 2026, 19:46 UTC

Correlated Moves
News

ADMA Biologics shares are lower following a securities fraud class action lawsuit alleging false statements and undisclosed transactions, amid broader negative market sentiment.

6. aug 2026, 20:02 UTC

News

ADMA Biologics reported second-quarter net income of $37.82 million and revenue of $124.40 million, driving shares higher during Thursday's session.

5. aug 2026, 23:02 UTC

News

ADMA Biologics reported second-quarter revenue of $124.4 million, missing expectations. Shares are lower in after-market trading following the earnings release.

4. aug 2026, 19:46 UTC

News

ADMA Biologics Inc. is trading higher, buoyed by strong momentum and a decline in crude oil prices that eases inflation concerns and supports consumer spending.

3. aug 2026, 19:16 UTC

ADMA Biologics Inc shares are higher today, continuing an upward trend since Friday amid broader market optimism following recent geopolitical developments.

31. juuli 2026, 20:06 UTC

News

ADMA Biologics is declining amid a class action lawsuit alleging fraudulent activities, continuing a trend of four consecutive lower sessions.

30. juuli 2026, 19:39 UTC

Correlated Moves

ADMA Biologics shares are lower following a decline in first-quarter performance, reflecting broader market sentiment amid ongoing investor concerns.

29. juuli 2026, 18:17 UTC

News
Correlated Moves

ADMA Biologics will report second-quarter 2026 results on August 5, contributing to today's higher share price amid steady trading.

28. juuli 2026, 20:06 UTC

News

ADMA Biologics Inc. is rising amid broader biotechnology sector strength, despite ongoing legal challenges. The stock has shown steady gains since Monday's close.

27. juuli 2026, 19:41 UTC

ADMA Biologics Inc shares are higher today, continuing a strong performance since Friday. No specific news was identified to explain the gains.

24. juuli 2026, 19:26 UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

22. juuli 2026, 18:36 UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

21. juuli 2026, 19:36 UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

20. juuli 2026, 19:46 UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Võrdlus sarnastega

Hinnamuutus

ADMA Biologics Inc Prognoos

Hinnasiht

By TipRanks

80.66% tõus

12 kuu keskmine prognoos

Keskmine 17 USD  80.66%

Kõrge 21 USD

Madal 12 USD

Põhineb 4 Wall Streeti analüütiku instrumendi ADMA Biologics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

3

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

325 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
help-icon Live chat